

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:57:11 ON 20 APR 2005

=> s nicotine or (nicotine derivative)

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an

index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file caplus uspatfull japiro epfull medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 18:57:57 ON 20 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 18:57:57 ON 20 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 18:57:57 ON 20 APR 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'EPFULL' ENTERED AT 18:57:57 ON 20 APR 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 18:57:57 ON 20 APR 2005

FILE 'BIOSIS' ENTERED AT 18:57:57 ON 20 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 18:57:57 ON 20 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 18:57:57 ON 20 APR 2005
Copyright (c) 2005 The Thomson Corporation

=> s nicotine or (nicotine derivative)
[1] 113468 NICOTINE OR (NICOTINE DERIVATIVE)

```
=> s 11 and (pharmaceutically acceptable carrier)
L2          2052 L1 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

=> s 12 and (intravenous? and transdermal? and oral? and intranasal? and
intravaginal?)
L3          47 L2 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANASAL?
AND INTRAVAGINAL?)
```

=> s 13 and (binding agent#)

=> d 14 1-10 ibib abs

L4 ANSWER 1 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:43717 USPATFULL
TITLE: Oncology drug innovation
INVENTOR(S): Poulsen, Hans Skovgaard, Hellerup, DENMARK
Pedersen, Nina, Copenhagen, DENMARK
Mortensen, Shila, Gentofte, DENMARK
Sorensen, Susanne Berg, Hellerup, DENMARK
Pedersen, Mikkel Wandahl, Copenhagen, DENMARK
Elsner, Henrik, Broenshoej, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005037445	A1	20050217
APPLICATION INFO.:	US 2004-482029	A1	20040903 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-992 US 2001-301818P	20010625 20010702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303	
NUMBER OF CLAIMS:	72	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	6269	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes methods for identification of molecules expressed at a different level on the cell surface of cancer cells compared to non-malignant cells and methods of identification of cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer. The invention furthermore describes targeting complexes targeted to cell surface molecules identified by the methods of the invention. In embodiments of the invention said targeting complexes comprise the promoters identified by the methods of the invention. In addition the invention describes methods of identifying binding partners for the cell surface molecules and the binding partners per se. Methods of treatment using the targeting complexes and uses of the targeting complexes for the preparation of a medicament are also disclosed by the invention. Furthermore, the invention describes uses of the cell surface molecules or fragments thereof for preparation of vaccines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2005:16454 USPATFULL
TITLE:	Cochleate compositions directed against expression of proteins
INVENTOR(S) :	Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES Mannino, Raphael J., Annandale, NJ, UNITED STATES Ahl, Patrick, Princeton, NJ, UNITED STATES Shang, Gaofeng, Livingston, NJ, UNITED STATES Chen, Zi Wei, Newark, NJ, UNITED STATES Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES
PATENT ASSIGNEE(S) :	BioDelivery Sciences International, Inc., Newark, NJ, UNITED STATES (U.S. corporation) University of Medicine and Dentistry of New Jersey, Newark, NJ, UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005013855	A1 20050120
APPLICATION INFO.:	US 2004-822235	A1 20040409 (10)

NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-461483P US 2003-463076P US 2003-502557P US 2003-499247P US 2003-532755P	20030409 (60) 20030415 (60) 20030911 (60) 20030828 (60) 20031224 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA,	

02109

NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 3768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:16453 USPATFULL
TITLE: Novel encochleation methods, cochleates and methods of use
INVENTOR(S): Mannino, Raphael J., Annandale, NJ, UNITED STATES
Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES
Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES
Delmarre, David, Jersey City, NJ, UNITED STATES
Lu, Ruying, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005013854	A1	20050120
APPLICATION INFO.:	US 2004-822230	A1	20040409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461483P	20030409 (60)
	US 2003-463076P	20030415 (60)
	US 2003-502557P	20030911 (60)
	US 2004-537252P	20040115 (60)
	US 2003-499247P	20030828 (60)
	US 2003-532755P	20031224 (60)
	US 2004-556192P	20040324 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 147
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 61 Drawing Page(s)
LINE COUNT: 4695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004009491 A1 20040115
APPLICATION INFO.: US 2002-264237 A1 20021004 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed
on 18 May 2001, PENDING

NUMBER	DATE
US 2000-205515P	20000519 (60)
Utility	
APPLICATION	
HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	18144

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

NUMBER	KIND	DATE
US 2004005579	A1	20040108
US 2002-264049	A1	20021004 (10)
Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

NUMBER	DATE
US 2000-209467P	20000607 (60)
Utility	
APPLICATION	
HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	18130

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:219663 USPATFULL
TITLE: Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM2
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152953	A1	20030814
APPLICATION INFO.:	US 2002-199869	A1	20020719 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-306577P	20010719 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	12606	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+alphaM2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:160075 USPATFULL
TITLE: Colon and colon cancer associated polynucleotides and polypeptides
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17981	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:145924 USPATFULL
TITLE: Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
INVENTOR(S): Bachmann, Martin, Winterthur, SWITZERLAND
Storni, Tazio, Viganello, SWITZERLAND
Maurer, Patrik, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Schwarz, Katrin, Schlieren, SWITZERLAND
Meijerink, Edwin, Zurich, SWITZERLAND

Lipowsky, Gerd, Zurich, SWITZERLAND
Pumpens, Paul, Riga, LATVIA
Cielens, Indulis, Riga, LATVIA
Renhoffa, Regina, Riga, LATVIA
Cytos Biotechnology AG (non-U.S. corporation)

PATENT ASSIGNEE(S) :

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003099668	A1	20030529
APPLICATION INFO.:	US 2002-244065	A1	20020916 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-318994P	20010914 (60)
	US 2002-374145P	20020422 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	207	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	60 Drawing Page(s)	
LINE COUNT:	7907	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2003:133508 USPATFULL
TITLE: In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
INVENTOR(S): Bachmann, Martin F., Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Storni, Tazio, Viganello, SWITZERLAND
PATENT ASSIGNEE(S): Cytos Biotechnology AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091593	A1	20030515
APPLICATION INFO.:	US 2002-243739	A1	20020916 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-318967P	20010914 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	194	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 6522

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:113075 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003077808	A1	20030424
APPLICATION INFO.:	US 2001-764891	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US	2000-225268P	20000814	(60)
US	2000-236368P	20000929	(60)
US	2000-251856P	20001208	(60)
US	2000-251868P	20001208	(60)
US	2000-229344P	20000901	(60)
US	2000-234997P	20000925	(60)
US	2000-229343P	20000901	(60)
US	2000-229345P	20000901	(60)
US	2000-229287P	20000901	(60)
US	2000-229513P	20000905	(60)
US	2000-231413P	20000908	(60)
US	2000-229509P	20000905	(60)
US	2000-236367P	20000929	(60)
US	2000-237039P	20001002	(60)
US	2000-237038P	20001002	(60)
US	2000-236370P	20000929	(60)
US	2000-236802P	20001002	(60)
US	2000-237037P	20001002	(60)
US	2000-237040P	20001002	(60)
US	2000-240960P	20001020	(60)
US	2000-239935P	20001013	(60)
US	2000-239937P	20001013	(60)
US	2000-241787P	20001020	(60)
US	2000-246474P	20001108	(60)
US	2000-246532P	20001108	(60)
US	2000-249216P	20001117	(60)
US	2000-249210P	20001117	(60)
US	2000-226681P	20000822	(60)
US	2000-225759P	20000814	(60)
US	2000-225213P	20000814	(60)
US	2000-227182P	20000822	(60)
US	2000-225214P	20000814	(60)
US	2000-235836P	20000927	(60)
US	2000-230438P	20000906	(60)
US	2000-215135P	20000630	(60)
US	2000-225266P	20000814	(60)
US	2000-249218P	20001117	(60)
US	2000-249208P	20001117	(60)
US	2000-249213P	20001117	(60)
US	2000-249212P	20001117	(60)
US	2000-249207P	20001117	(60)
US	2000-249245P	20001117	(60)
US	2000-249244P	20001117	(60)
US	2000-249217P	20001117	(60)
US	2000-249211P	20001117	(60)
US	2000-249215P	20001117	(60)
US	2000-249264P	20001117	(60)
US	2000-249214P	20001117	(60)
US	2000-249297P	20001117	(60)
US	2000-232400P	20000914	(60)
US	2000-231242P	20000908	(60)
US	2000-232081P	20000908	(60)
US	2000-232080P	20000908	(60)
US	2000-231414P	20000908	(60)
US	2000-231244P	20000908	(60)
US	2000-233064P	20000914	(60)
US	2000-233063P	20000914	(60)
US	2000-232397P	20000914	(60)
US	2000-232399P	20000914	(60)
US	2000-232401P	20000914	(60)
US	2000-241808P	20001020	(60)
US	2000-241826P	20001020	(60)
US	2000-241786P	20001020	(60)

US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

24

EXEMPLARY CLAIM:

1

LINE COUNT:

59131

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated

polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:57:11 ON 20 APR 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE,
SCISEARCH' ENTERED AT 18:57:57 ON 20 APR 2005

L1 113468 S NICOTINE OR (NICOTINE DERIVATIVE)
L2 2052 S L1 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)
L3 47 S L2 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANASAL?)
L4 10 S L3 AND (BINDING AGENT#)

=> s L1 and (metabolite or (degradation product)

UNMATCHED LEFT PARENTHESIS 'AND (METABOLITE'

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s L1 and (metabolite or (degradation product))

L5 3873 L1 AND (METABOLITE OR (DEGRADATION PRODUCT))

=> s 16 and (pharmaceutically acceptable carrier)

L6 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (>).

=> .

. IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (>).

=> L5

L5 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (>).

=>

<-----User Break----->

=> s 15 and (pharmaceutically acceptable carrier)

L6 295 L5 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

=> s 16 and (intravenous? and transdermal? and oral? and intranasal? and intravaginal?)

L7 14 L6 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANASAL? AND INTRAVAGINAL?)

=> d 17 1-14 ibib abs

L7 ANSWER 1 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2005:93400 USPATFULL
 TITLE: Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter
 INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
 Bannister, Thomas D., Northborough, MA, UNITED STATES
 Cuny, Gregory D., Somerville, MA, UNITED STATES
 Hauske, James R., Concord, MA, UNITED STATES
 Holland, Joanne M., Brookline, MA, UNITED STATES
 Persons, Paul E., Westborough, MA, UNITED STATES
 Radeke, Heike S., South Grafton, MA, UNITED STATES
 Wang, Fengjiang, Northborough, MA, UNITED STATES
 Shao, Liming, Lincoln, MA, UNITED STATES
 PATENT ASSIGNEE(S): Sepracor, Inc., Marlborough, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005080078	A1	20050414
APPLICATION INFO.:	US 2004-771519	A1	20040204 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-607457, filed on 26 Jun 2003, PENDING Division of Ser. No. US 2001-951130, filed on 12 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-273530P	20010305 (60)
	US 2001-298057P	20010613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	70	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	8631	
AB	One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.	

L7 ANSWER 2 OF 14 USPATFULL on STN
 ACCESSION NUMBER: 2004:145035 USPATFULL
 TITLE: Method of treating neurological diseases
 INVENTOR(S): Maden, Malcom, Middlesex, UNITED KINGDOM
 Corcoran, Jonathan Patrick Thomas, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110707	A1	20040610
APPLICATION INFO.:	US 2004-468244	A1	20040120 (10)
	WO 2002-GB663		20020215
PRIORITY INFORMATION:	GB 2001-3998	20010219	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606		

NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 1882

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating a condition in a subject comprising administering an effective amount of an agent to said subject wherein said agent modulates one or more components of the retinoid signaling pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2003:282299 USPATFULL
TITLE: Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Zhang, Jun, San Diego, CA, UNITED STATES
Wei, Ping, Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198640	A1	20031023
APPLICATION INFO.:	US 2002-310793	A1	20021206 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-226294, filed		

on 23 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2001-899059, filed on 6 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-559290, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-246129, filed on 8 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-131237, filed on 7 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-5020, filed on 9 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1995-461246, filed on 5 Jun 1995, ABANDONED Continuation-in-part of Ser. No. WO 1994-US12880, filed on 7 Nov 1994, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336695P US 2001-314381P US 2001-278449P US 2000-216879P US 2000-180908P US 1999-134067P US 1999-132227P US 1999-131963P US 1998-74047P	20011207 (60) 20010824 (60) 20010326 (60) 20000707 (60) 20000208 (60) 19990513 (60) 19990503 (60) 19990430 (60) 19980209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	14726	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention encompasses methods for detection, diagnosis, prevention, treatment, and/or amelioration of inflammatory bowel diseases and disorders using TNF-gamma- β and its receptors DR3 and TR6. In particular the invention encompasses methods of using TNF-gamma- β , DR3 and TR6 polypeptides, as well as antibodies, and antagonists thereto, in the diagnosis, prognosis and treatment of ulcerative colitis and/or Crohn's disease. Methods of screening for antagonists of the TNF-gamma- β polypeptide, together with therapeutic uses of such antagonists are also disclosed.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
L7 ANSWER 6 OF 14	USPATFULL on STN	
ACCESSION NUMBER:	2003:244856 USPATFULL	
TITLE:	Therapeutic compositions and methods relating to prolactin releasing peptide (PrRP)	
INVENTOR(S):	Civelli, Olivier, Irvine, CA, UNITED STATES Lin, Steven, Upland, CA, UNITED STATES	
PATENT ASSIGNEE(S):	Regents of the University of California (U.S. corporation)	
NUMBER KIND DATE		
PATENT INFORMATION:	US 2003171270	A1 20030911
APPLICATION INFO.:	US 2002-96777	A1 20020312 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-560915, filed on 28 Apr 2000, GRANTED, Pat. No. US 6383764	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122	

NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1706

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a substantially pure Prolactin Releasing Peptide (PrRP) functional analog which suppresses absence seizures in a mammal, and related pharmaceutical compositions. The invention also provides a method of controlling absence seizures in a mammal, by administering to a mammal susceptible to absence seizures an effective amount of PrRP or a PrRP functional analog. Also provided are methods of identifying a compound that modulates AMPA receptor signaling in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to modulate AMPA receptor signaling. The invention also provides methods of identifying a compound for controlling absence seizures in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to control absence seizures in a mammal. Also provided are pharmaceutical compositions for controlling absence seizures in a mammal. The compositions and related methods contain a compound identified by the methods of the invention as a compound that modulates AMPA receptor signaling or as a compound that controls absence seizures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2003:160075 USPATFULL
TITLE: Colon and colon cancer associated polynucleotides and polypeptides
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17981	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and

antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:145924 USPATFULL
TITLE: Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
INVENTOR(S): Bachmann, Martin, Winterthur, SWITZERLAND
 Storni, Tazio, Viganello, SWITZERLAND
 Maurer, Patrik, Winterthur, SWITZERLAND
 Tissot, Alain, Zurich, SWITZERLAND
 Schwarz, Katrin, Schlieren, SWITZERLAND
 Meijerink, Edwin, Zurich, SWITZERLAND
 Lipowsky, Gerd, Zurich, SWITZERLAND
 Pumpens, Paul, Riga, LATVIA
 Cielens, Indulis, Riga, LATVIA
 Renhofa, Regina, Riga, LATVIA
PATENT ASSIGNEE(S): Cytos Biotechnology AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003099668	A1	20030529
APPLICATION INFO.:	US 2002-244065	A1	20020916 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-318994P	20010914 (60)
	US 2002-374145P	20020422 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	

NUMBER OF CLAIMS: 207

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 60 Drawing Page(s)

LINE COUNT: 7907

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2003:133508 USPATFULL
TITLE: In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
INVENTOR(S): Bachmann, Martin F., Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Storni, Tazio, Viganello, SWITZERLAND
PATENT ASSIGNEE(S): Cytos Biotechnology AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091593	A1	20030515
APPLICATION INFO.:	US 2002-243739	A1	20020916 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-318967P	20010914 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	194	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	6522	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2003:93613 USPATFULL
TITLE: Methods for inhibiting cognitive deterioration in adults with down's syndrome
INVENTOR(S): Belanoff, Joseph K., Woodside, CA, UNITED STATES
PATENT ASSIGNEE(S): Corcept Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064974	A1	20030403
APPLICATION INFO.:	US 2002-230575	A1	20020828 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-316653P	20010831 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	

NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 1295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:102277 USPATFULL
TITLE: Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
INVENTOR(S): Civelli, Olivier, Irvine, CA, United States
Lin, Steven, Upland, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383764	B1	20020507
APPLICATION INFO.:	US 2000-560915		20000428 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
ASSISTANT EXAMINER:	DeBerry, Regina M.		
LEGAL REPRESENTATIVE:	Campbell & Flores LLP		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1555		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a substantially pure Prolactin Releasing Peptide (PrRP) functional analog which suppresses absence seizures in a mammal, and related pharmaceutical compositions. The invention also provides a method of controlling absence seizures in a mammal, by administering to a mammal susceptible to absence seizures an effective amount of PrRP or a PrRP functional analog. Also provided are methods of identifying a compound that modulates AMPA receptor signaling in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to modulate AMPA receptor signaling. The invention also provides methods of identifying a compound for controlling absence seizures in a mammal, by providing a compound that is a PrRP or PrRP functional analog, and determining the ability of the compound to control absence seizures in a mammal. Also provided are pharmaceutical compositions for controlling absence seizures in a mammal. The compositions and related methods contain a compound identified by the methods of the invention as a compound that modulates AMPA receptor signaling or as a compound that controls absence seizures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:66880 USPATFULL

TITLE: Screening and therapeutic methods for promoting wakefulness and sleep

INVENTOR(S): Civelli, Olivier, Irvine, CA, UNITED STATES
Lin, Steven, Upland, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002037533 A1 20020328

APPLICATION INFO.: US 2001-932161 A1 20010817 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-560915, filed on 28 Apr 2000, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 2464

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods of screening for a compound for promoting wakefulness in a mammal. The method is practiced by providing a compound that is a PrRP receptor agonist and determining the ability of the compound to promote wakefulness. Also provided by the invention are methods of screening for a compound for promoting sleep in a mammal. The methods are practiced by providing a compound that is a PrRP receptor antagonist and determining the ability of the compound to promote sleep. In addition, the invention provides a method of promoting wakefulness in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor agonist. The invention further provides a method of promoting sleep in a mammal. The method is practiced by administering to a mammal an effective amount of a PrRP receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:63894 USPATFULL

TITLE: Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists

INVENTOR(S): Schatzberg, Alan F., Los Altos, CA, United States
Belanoff, Joseph K., Cupertino, CA, United States

PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6362173 B1 20020326

APPLICATION INFO.: US 2000-639377 20000815 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-244457, filed on 4 Feb 1999, now patented, Pat. No. US 6150349 Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998

NUMBER DATE

PRIORITY INFORMATION: US 1997-60973P 19971006 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Jarvis, William R. A.

LEGAL REPRESENTATIVE: Field, Bret E., Bozicevic, Field & Francis

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer's Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2000:157400 USPATFULL

TITLE: Methods for treating psychosis associated with glucocorticoid related dysfunction

INVENTOR(S): Schatzberg, Alan F., Los Altos, CA, United States

Belanoff, Joseph K., Cupertino, CA, United States

PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6150349 20001121

APPLICATION INFO.: US 1999-244457 19990204 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-60973P 19971006 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Jarvis, William R. A.

LEGAL REPRESENTATIVE: Bozicevic, Field & Francis

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

LINE COUNT: 1515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating psychotic major depression. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:57:11 ON 20 APR 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 18:57:57 ON 20 APR 2005

L1 113468 S NICOTINE OR (NICOTINE DERIVATIVE)

L2 2052 S L1 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

L3 47 S L2 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS

L4 10 S L3 AND (BINDING AGENT#)

L5 3873 S L1 AND (METABOLITE OR (DEGRADATION PRODUCT))
L6 295 S L5 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)
L7 14 S L6 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS

=> d 13 1-47

L3 ANSWER 1 OF 47 USPATFULL on STN
AN 2005:93400 USPATFULL
TI Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter
IN Aquila, Brian M., Marlborough, MA, UNITED STATES
 Bannister, Thomas D., Northborough, MA, UNITED STATES
 Cuny, Gregory D., Somerville, MA, UNITED STATES
 Hauske, James R., Concord, MA, UNITED STATES
 Holland, Joanne M., Brookline, MA, UNITED STATES
 Persons, Paul E., Westborough, MA, UNITED STATES
 Radeke, Heike S., South Grafton, MA, UNITED STATES
 Wang, Fengjiang, Northborough, MA, UNITED STATES
 Shao, Liming, Lincoln, MA, UNITED STATES
PA Sepracor, Inc., Marlborough, MA, UNITED STATES (U.S. corporation)
PI US 2005080078 A1 20050414
AI US 2004-771519 A1 20040204 (10)
RLI Continuation-in-part of Ser. No. US 2003-607457, filed on 26 Jun 2003,
 PENDING Division of Ser. No. US 2001-951130, filed on 12 Sep 2001,
 PENDING
PRAI US 2001-273530P 20010305 (60)
 US 2001-298057P 20010613 (60)
DT Utility
FS APPLICATION
LN.CNT 8631
INCL INCLM: 514/227.500
 INCLS: 514/237.500; 514/255.010; 514/255.020; 514/317.000
NCL NCLM: 514/227.500
 NCLS: 514/237.500; 514/255.010; 514/255.020; 514/317.000
IC [7]
 ICM: A61K031-54
 ICS: A61K031-537; A61K031-496; A61K031-495; A61K031-445

L3 ANSWER 2 OF 47 USPATFULL on STN
AN 2005:75887 USPATFULL
TI Aryl or heteroaryl amide compounds
IN Nakao, Kazunari, Aichi-ken, JAPAN
 Nukui, Seiji, San Diego, CA, UNITED STATES
 Okumura, Yoshiyuki, Aichi-ken, JAPAN
 Yamagishi, Tatsuya, Aichi-ken, JAPAN
PI US 2005065188 A1 20050324
AI US 2004-932463 A1 20040902 (10)
PRAI US 2003-500131P 20030903 (60)
DT Utility
FS APPLICATION
LN.CNT 6313
INCL INCLM: 514/341.000
 INCLS: 514/356.000; 514/381.000; 514/601.000; 514/563.000; 546/268.100;
 546/315.000; 562/450.000; 564/086.000
NCL NCLM: 514/341.000
 NCLS: 514/356.000; 514/381.000; 514/601.000; 514/563.000; 546/268.100;
 546/315.000; 562/450.000; 564/086.000
IC [7]
 ICM: A61K031-4439
 ICS: A61K031-355; A61K031-198; A61K031-195; A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 47 USPATFULL on STN

AN 2005:69530 USPATFULL
TI Therapeutic agents useful for treating pain
IN Sun, Qun, Princeton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES
PI US 2005059671 A1 20050317
AI US 2003-669823 A1 20030923 (10)
PRAI US 2002-412847P 20020924 (60)
DT Utility
FS APPLICATION
LN.CNT 7623
INCL INCLM: 514/253.010
INCLS: 514/253.090; 544/360.000
NCL NCLM: 514/253.010
NCLS: 514/253.090; 544/360.000
IC [7]
ICM: A61K031-496
ICS: C07D043-14; C07D043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 47 USPATFULL on STN
AN 2005:44234 USPATFULL
TI Keratinocyte growth factor-2
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Jimenez, Pablo, Chatham, NJ, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Rampy, Mark A., Montgomery Village, MD, UNITED STATES
Mendrick, Donna, Mount Airy, MD, UNITED STATES
Zhang, Jun, San Diego, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Moore, Paul A., North Bethesda, MD, UNITED STATES
Coleman, Timothy A., Derwood, MD, UNITED STATES
Gruber, Joachim R., Dallas, TX, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2005037966 A1 20050217
AI US 2004-901210 A1 20040729 (10)
RLI Division of Ser. No. US 2002-35212, filed on 4 Jan 2002, PENDING
PRAI US 2001-259853P 20010108 (60)
US 2001-286368P 20010426 (60)
US 2001-331168P 20011109 (60)
DT Utility
FS APPLICATION
LN.CNT 17190
INCL INCLM: 514/012.000
INCLS: 514/044.000; 530/399.000
NCL NCLM: 514/012.000
NCLS: 514/044.000; 530/399.000
IC [7]
ICM: A61K038-18
ICS: A61K048-00; C07K014-475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 47 USPATFULL on STN
AN 2005:43717 USPATFULL
TI Oncology drug innovation
IN Poulsen, Hans Skovgaard, Hellerup, DENMARK
Pedersen, Nina, Copenhagen, DENMARK
Mortensen, Shila, Gentofte, DENMARK
Sorensen, Susanne Berg, Hellerup, DENMARK
Pedersen, Mikkel Wandahl, Copenhagen, DENMARK
Elsner, Henrik, Broenshoej, DENMARK
PI US 2005037445 A1 20050217

AI US 2004-482029 A1 20040903 (10)
WO 2002-IB3534 20020619

PRAI DK 2001-992 20010625
US 2001-301818P 20010702 (60)

DT Utility
FS APPLICATION
LN.CNT 6269

INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 47 USPATFULL on STN
AN 2005:24082 USPATFULL
TI 3-Substituted benzofurans as therapeutic agents
IN Gogliotti, Rocco Dean, Pinckney, MI, UNITED STATES
Lee, Helen Tsenwhei, Ann Arbor, MI, UNITED STATES
Sexton, Karen Elaine, Chelsea, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES

PI US 2005020631 A1 20050127
AI US 2004-860527 A1 20040603 (10)
PRAI US 2003-476251P 20030605 (60)

DT Utility
FS APPLICATION
LN.CNT 1466

INCL INCLM: 514/320.000
INCLS: 514/381.000; 546/196.000; 548/251.000
NCL NCLM: 514/320.000
NCLS: 514/381.000; 546/196.000; 548/251.000
IC [7]
ICM: A61K031-454
ICS: C07D045-14; A61K031-41

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 47 USPATFULL on STN
AN 2005:24081 USPATFULL
TI Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
IN Connolly, Michael, Ypsilanti, MI, UNITED STATES
Gogliotti, Rocco Dean, Pinckney, MI, UNITED STATES
Lee, Helen Tsenwhei, Ann Arbor, MI, UNITED STATES
Plummer, Mark Stephen, Dexter, MI, UNITED STATES
Sexton, Karen Elaine, Chelsea, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES

PI US 2005020630 A1 20050127
AI US 2004-860524 A1 20040603 (10)
PRAI US 2003-476073P 20030605 (60)

DT Utility
FS APPLICATION
LN.CNT 1661

INCL INCLM: 514/320.000
INCLS: 514/381.000; 546/196.000; 548/251.000
NCL NCLM: 514/320.000
NCLS: 514/381.000; 546/196.000; 548/251.000
IC [7]
ICM: C07D049-14
ICS: A61K031-454; A61K031-41

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 47 USPATFULL on STN
AN 2005:16454 USPATFULL
TI Cochleate compositions directed against expression of proteins

IN Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES
Mannino, Raphael J., Annandale, NJ, UNITED STATES
Ahl, Patrick, Princeton, NJ, UNITED STATES
Shang, Gaofeng, Livingston, NJ, UNITED STATES
Chen, Zi Wei, Newark, NJ, UNITED STATES
Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES
PA BioDelivery Sciences International, Inc., Newark, NJ, UNITED STATES
(U.S. corporation)
University of Medicine and Dentistry of New Jersey, Newark, NJ, UNITED
STATES (U.S. corporation)
PI US 2005013855 A1 20050120
AI US 2004-822235 A1 20040409 (10)
PRAI US 2003-461483P 20030409 (60)
US 2003-463076P 20030415 (60)
US 2003-502557P 20030911 (60)
US 2003-499247P 20030828 (60)
US 2003-532755P 20031224 (60)
DT Utility
FS APPLICATION
LN.CNT 3768
INCL INCLM: 424/450.000
INCLS: 536/023.100; 514/044.000
NCL NCLM: 424/450.000
NCLS: 536/023.100; 514/044.000
IC [7]
ICM: A61K048-00
ICS: A61K009-127; C07H021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 47 USPATFULL on STN
AN 2005:16453 USPATFULL
TI Novel encochleation methods, cochleates and methods of use
IN Mannino, Raphael J., Annandale, NJ, UNITED STATES
Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES
Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES
Delmarre, David, Jersey City, NJ, UNITED STATES
Lu, Ruying, New Providence, NJ, UNITED STATES
PI US 2005013854 A1 20050120
AI US 2004-822230 A1 20040409 (10)
PRAI US 2003-461483P 20030409 (60)
US 2003-463076P 20030415 (60)
US 2003-502557P 20030911 (60)
US 2004-537252P 20040115 (60)
US 2003-499247P 20030828 (60)
US 2003-532755P 20031224 (60)
US 2004-556192P 20040324 (60)
DT Utility
FS APPLICATION
LN.CNT 4695
INCL INCLM: 424/450.000
INCLS: 435/458.000
NCL NCLM: 424/450.000
NCLS: 435/458.000
IC [7]
ICM: A61K031-70
ICS: A61K009-127; C12N015-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 47 USPATFULL on STN
AN 2005:10554 USPATFULL
TI Cochleate preparations of fragile nutrients
IN Mannino, Raphael J., Annandale, NJ, UNITED STATES
Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES

Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES
Delmarre, David, Jersey City, NJ, UNITED STATES
Tan, Feng, Newark, NJ, UNITED STATES
PI US 2005008686 A1 20050113
AI US 2004-759381 A1 20040115 (10)
PRAI US 2003-440120P 20030115 (60)
US 2003-465754P 20030425 (60)
DT Utility
FS APPLICATION
LN.CNT 1204
INCL INCLM: 424/450.000
NCL NCLM: 424/450.000
IC [7]
ICM: A61K009-127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 47 USPATFULL on STN
AN 2005:5089 USPATFULL
TI 3-Substituted indoles and derivatives thereof as therapeutic agents
IN Para, Kimberly Suzanne, Ann Arbor, MI, UNITED STATES
Stankovic, Charles John, Saline, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES
PI US 2005004195 A1 20050106
AI US 2004-860336 A1 20040603 (10)
PRAI US 2003-475992P 20030605 (60)
DT Utility
FS APPLICATION
LN.CNT 1064
INCL INCLM: 514/381.000
INCLS: 548/251.000
NCL NCLM: 514/381.000
NCLS: 548/251.000
IC [7]
ICM: A61K031-41
ICS: C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 47 USPATFULL on STN
AN 2004:328101 USPATFULL
TI 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as
therapeutic agents
IN Bruendl, Michelle M., Ann Arbor, MI, UNITED STATES
Connolly, Michael, Ypsilanti, MI, UNITED STATES
Goodman, Annise Paige, West Bloomfield, MI, UNITED STATES
Gigliotti, Rocco Dean, Pinckney, MI, UNITED STATES
Lee, Helen Tsenwhei, Ann Arbor, MI, UNITED STATES
Plummer, Mark Stephen, Dexter, MI, UNITED STATES
Sexton, Karen Elaine, Chelsea, MI, UNITED STATES
Shahripour, Aurash B., Ann Arbor, MI, UNITED STATES
Reichard, Greg, Ann Arbor, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PI US 2004259926 A1 20041223
AI US 2004-860348 A1 20040603 (10)
PRAI US 2003-475970P 20030605 (60)
DT Utility
FS APPLICATION
LN.CNT 2901
INCL INCLM: 514/381.000
INCLS: 548/251.000
NCL NCLM: 514/381.000
NCLS: 548/251.000
IC [7]

ICM: A61K031-41

ICS: C07D049-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 47 USPATFULL on STN
AN 2004:315277 USPATFULL
TI Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents
IN Gagliotti, Rocco Dean, Pinckney, MI, UNITED STATES
Lee, Helen Tsenwhei, Ann Arbor, MI, UNITED STATES
Sexton, Karen Elaine, Chelsea, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES
PI US 2004248954 A1 20041209
AI US 2004-859856 A1 20040603 (10)
PRAI US 2003-475971P 20030605 (60)
DT Utility
FS APPLICATION
LN.CNT 1300
INCL INCLM: 514/381.000
INCLS: 548/251.000
NCL NCLM: 514/381.000
NCLS: 548/251.000
IC [7]
ICM: A61K031-41
ICS: C07D049-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 47 USPATFULL on STN
AN 2004:315276 USPATFULL
TI 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents
IN Gagliotti, Rocco Dean, Pinckney, MI, UNITED STATES
Lee, Helen Tsenwhei, Ann Arbor, MI, UNITED STATES
Sexton, Karen Elaine, Chelsea, MI, UNITED STATES
Visnick, Melean, Ann Arbor, MI, UNITED STATES
PI US 2004248953 A1 20041209
AI US 2004-859854 A1 20040603 (10)
PRAI US 2003-476057P 20030605 (60)
DT Utility
FS APPLICATION
LN.CNT 1656
INCL INCLM: 514/381.000
INCLS: 548/251.000
NCL NCLM: 514/381.000
NCLS: 548/251.000
IC [7]
ICM: A61K031-41
ICS: C07D049-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 47 USPATFULL on STN
AN 2004:299984 USPATFULL
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
PI US 2004235853 A1 20041125
AI US 2003-625708 A1 20030724 (10)
PRAI US 2002-416525P 20021008 (60)
US 2002-413155P 20020925 (60)
US 2002-411020P 20020917 (60)
US 2002-398594P 20020726 (60)
DT Utility
FS APPLICATION
LN.CNT 5604

INCL INCLM: 514/252.020
INCLS: 544/238.000
NCL NCLM: 514/252.020
NCLS: 544/238.000
IC [7]
ICM: C07D043-04
ICS: A61K031-501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 47 USPATFULL on STN
AN 2004:286225 USPATFULL
TI Keratinocyte growth factor-2
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Jimenez, Pablo, Chatham, NJ, UNITED STATES
Duan, D. Roxanne, Gaithersburg, MD, UNITED STATES
Rampy, Mark A., Montgomery Village, MD, UNITED STATES
Mendrick, Donna, Mount Airy, MD, UNITED STATES
Zhang, Jun, San Diego, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Gruber, Joachim R., Dallas, TX, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
PA Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)
PI US 2004224387 A1 20041111
AI US 2003-733311 A1 20031212 (10)
RLI Division of Ser. No. US 2000-610651, filed on 30 Jun 2000, GRANTED, Pat. No. US 6693077 Continuation-in-part of Ser. No. US 1999-345373, filed on 1 Jul 1999, PENDING Continuation of Ser. No. US 1998-23082, filed on 13 Feb 1998, GRANTED, Pat. No. US 6077692 Continuation-in-part of Ser. No. US 1997-862432, filed on 23 May 1997, ABANDONED Division of Ser. No. US 1995-461195, filed on 5 Jun 1995, ABANDONED Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995, PENDING Continuation-in-part of Ser. No. US 1997-910875, filed on 13 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-696135, filed on 13 Aug 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-461195, filed on 5 Jun 1995, ABANDONED
PRAI US 2000-205417P 20000519 (60)
US 2000-198322P 20000419 (60)
US 1999-171677P 19991222 (60)
US 1999-163375P 19991103 (60)
US 1999-149935P 19990819 (60)
US 1999-148628P 19990812 (60)
US 1999-144024P 19990715 (60)
US 1999-143648P 19990714 (60)
US 1999-142343P 19990702 (60)
US 1997-39045P 19970228 (60)
US 1997-55561P 19970813 (60)
US 1996-23852P 19960813 (60)
DT Utility
FS APPLICATION
LN.CNT 16382
INCL INCLM: 435/069.100
INCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K038-18
ICS: C07H021-04; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 47 USPATFULL on STN

AN 2004:240296 USPATFULL
TI Therapeutic agents useful for treating pain
IN Sun, Qun, Princeton, NJ, UNITED STATES
Tafesse, Laykea, Robinsville, NJ, UNITED STATES
Victory, Sam, Newtown, PA, UNITED STATES
PI US 2004186111 A1 20040923
AI US 2003-739190 A1 20031219 (10)
PRAI US 2002-435917P 20021224 (60)
US 2003-459626P 20030403 (60)
US 2003-473856P 20030529 (60)
DT Utility
FS APPLICATION
LN.CNT 24955
INCL INCLM: 514/252.190
INCLS: 514/253.100; 544/295.000; 544/360.000
NCL NCLM: 514/252.190
NCLS: 514/253.100; 544/295.000; 544/360.000
IC [7]
ICM: C07D417-14
ICS: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 47 USPATFULL on STN
AN 2004:204016 USPATFULL
TI (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
IN Lippa, Arnold Stan, Ridgewood, NJ, UNITED STATES
Epstein, Joseph William, Monroe, NY, UNITED STATES
PA DOV Pharmaceutical, Inc. (U.S. corporation)
PI US 2004157908 A1 20040812
AI US 2004-764375 A1 20040123 (10)
RLI Division of Ser. No. US 2003-425545, filed on 29 Apr 2003, GRANTED, Pat. No. US 6716868 Division of Ser. No. US 2001-939071, filed on 24 Aug 2001, GRANTED, Pat. No. US 6569887
DT Utility
FS APPLICATION
LN.CNT 1255
INCL INCLM: 514/412.000
NCL NCLM: 514/412.000
IC [7]
ICM: A61K031-407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 47 USPATFULL on STN
AN 2004:203978 USPATFULL
TI (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
IN Lippa, Arnold Stan, Ridgewood, NJ, UNITED STATES
Epstein, Joseph William, Monroe, NY, UNITED STATES
PI US 2004157870 A1 20040812
AI US 2004-764373 A1 20040123 (10)
RLI Division of Ser. No. US 2003-425545, filed on 29 Apr 2003, GRANTED, Pat. No. US 6716868 Division of Ser. No. US 2001-939071, filed on 24 Aug 2001, GRANTED, Pat. No. US 6569887
DT Utility
FS APPLICATION
LN.CNT 1255
INCL INCLM: 514/278.000
INCLS: 546/015.000
NCL NCLM: 514/278.000
NCLS: 546/015.000
IC [7]
ICM: A61K031-4747

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 47 USPATFULL on STN
AN 2004:203977 USPATFULL
TI (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
IN Lippa, Arnold Stan, Ridgewood, NJ, UNITED STATES
Epstein, Joseph William, Monroe, NY, UNITED STATES
PA DOV Pharmaceutical, Inc. (U.S. corporation)
PI US 2004157869 A1 20040812
AI US 2004-764371 A1 20040123 (10)
RLI Division of Ser. No. US 2003-425545, filed on 29 Apr 2003, GRANTED, Pat. No. US 6716868 Division of Ser. No. US 2001-939071, filed on 24 Aug 2001, GRANTED, Pat. No. US 6569887
DT Utility
FS APPLICATION
LN.CNT 1256
INCL INCLM: 514/278.000
INCLS: 546/015.000
NCL NCLM: 514/278.000
NCLS: 546/015.000
IC [7]
ICM: A61K031-4747

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 47 USPATFULL on STN
AN 2004:189783 USPATFULL
TI Geodate delivery vehicles
IN Mannino, Raphael J., Annandale, NJ, UNITED STATES
Krause-Elsmore, Sara L., Kearny, NJ, UNITED STATES
Gould-Fogerite, Susan, Annandale, NJ, UNITED STATES
Delmarre, David, Jersey City, NJ, UNITED STATES
Lu, Ruying, New Providence, NJ, UNITED STATES
PA BioDelivery Sciences International, Inc., Newark, NJ (U.S. corporation)
PI US 2004146551 A1 20040729
AI US 2003-701364 A1 20031103 (10)
PRAI US 2002-422989P 20021101 (60)
US 2003-440284P 20030114 (60)
US 2003-507361P 20030929 (60)
DT Utility
FS APPLICATION
LN.CNT 1638
INCL INCLM: 424/450.000
NCL NCLM: 424/450.000
IC [7]
ICM: A61K009-127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 47 USPATFULL on STN
AN 2004:166011 USPATFULL
TI Therapeutic agents useful for treating pain
IN Chen, Zhengming, Belle Mead, NJ, UNITED STATES
Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
PI US 2004127501 A1 20040701
AI US 2003-669875 A1 20030923 (10)
PRAI US 2002-413193P 20020924 (60)
US 2003-456042P 20030319 (60)
DT Utility
FS APPLICATION
LN.CNT 8534
INCL INCLM: 514/252.140
INCLS: 544/295.000; 514/252.180; 514/252.190
NCL NCLM: 514/252.140

IC NCLS: 544/295.000; 514/252.180; 514/252.190
[7]
ICM: A61K031-506
ICS: C07D043-14; C07D043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 47 USPATFULL on STN
AN 2004:159412 USPATFULL
TI Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
IN Nielsen, Jacob, Copenhagen, DENMARK
Pedersen, Jan Torleif, Bronshoj, DENMARK
Gerwien, Jens, Copenhagen, DENMARK
Bay, Katrine, Copenhagen, DENMARK
Pedersen, Lars Ostergaard, Copenhagen, DENMARK
Leist, Marcel, Valby, DENMARK
Geist, Marie Aavang, Valby, DENMARK
Kallunki, Pekka, Copenhagen, DENMARK
Christensen, Soren, Jyllinge, DENMARK
Sager, Thomas, Smorum, DENMARK
Brines, Michael, Woodbridge, CT, UNITED STATES
Cerami, Anthony, Somers, NY, UNITED STATES
Cerami, Carla, Sleepy Hollow, NY, UNITED STATES
PI US 2004122216 A1 20040624
AI US 2003-612665 A1 20030701 (10)
PRAI US 2002-392455P 20020701 (60)
US 2002-393423P 20020703 (60)
DT Utility
FS APPLICATION
LN.CNT 9407
INCL INCLM: 530/351.000
NCL NCLM: 530/351.000
IC [7]
ICM: C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 47 USPATFULL on STN
AN 2004:145035 USPATFULL
TI Method of treating neurological diseases
IN Maden, Malcom, Middlesex, UNITED KINGDOM
Corcoran, Jonathan Patrick Thomas, London, UNITED KINGDOM
PI US 2004110707 A1 20040610
AI US 2004-468244 A1 20040120 (10)
WO 2002-GB663 20020215
PRAI GB 2001-3998 20010219
DT Utility
FS APPLICATION
LN.CNT 1882
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 47 USPATFULL on STN
AN 2004:139449 USPATFULL
TI Therapeutic agents useful for treating pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
Tafesse, Laykea, Robbinsville, NJ, UNITED STATES
Zhang, Chongwu, Dayton, NJ, UNITED STATES
Zhou, Xiaoming, Plainsboro, NJ, UNITED STATES

PI US 2004106625 A1 20040603
AI US 2003-607563 A1 20030627 (10)
PRAI US 2002-391962P 20020628 (60)
US 2002-411030P 20020917 (60)
US 2002-413148P 20020925 (60)
US 2002-416582P 20021008 (60)

DT Utility
FS APPLICATION

LN.CNT 8691

INCL INCLM: 514/253.010

INCLS: 544/360.000

NCL NCLM: 514/253.010

NCLS: 544/360.000

IC [7]

ICM: A61K031-496

ICS: C07D043-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 47 USPATFULL on STN

AN 2004:57996 USPATFULL

TI Therapeutic agents useful for treating pain

IN Kyle, Donald J., Newtown, PA, UNITED STATES

Qun, Sun, Princeton, NJ, UNITED STATES

PI US 20040444003 A1 20040304

AI US 2003-355186 A1 20030131 (10)

PRAI US 2002-352855P 20020201 (60)

US 2002-411043P 20020917 (60)

DT Utility

FS APPLICATION

LN.CNT 4567

INCL INCLM: 514/253.010

INCLS: 514/282.000; 544/360.000

NCL NCLM: 514/253.010

NCLS: 514/282.000; 544/360.000

IC [7]

ICM: A61K031-496

ICS: A61K031-485; C07D043-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 47 USPATFULL on STN

AN 2004:41451 USPATFULL

TI Keratinocyte growth factor-2

IN Ruben, Steven M., Brookeville, MD, United States

Jimenez, Pablo, Chatham, NJ, United States

Duan, D. Roxanne, Gaithersburg, MD, United States

Rampy, Mark A., Montgomery Village, MD, United States

Mendrick, Donna, Mount Airy, MD, United States

Zhang, Jun, San Diego, CA, United States

NI, Jian, Germantown, MD, United States

Moore, Paul A., North Bethesda, MD, United States

Coleman, Timothy A., Gaithersburg, MD, United States

Gruber, Joachim R., Dallas, TX, United States

Dillon, Patrick J., Carlsbad, CA, United States

Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL

PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

PI US 6693077 B1 20040217

AI US 2000-610651 20000630 (9)

RLI Continuation-in-part of Ser. No. US 1999-345373, filed on 1 Jul 1999

Continuation of Ser. No. US 1998-23082, filed on 13 Feb 1998, now

patented, Pat. No. US 6077692 Continuation-in-part of Ser. No. US

1997-910875, filed on 13 Aug 1997 Continuation-in-part of Ser. No. US

1997-862432, filed on 23 May 1997 Division of Ser. No. US 1995-461195,

filed on 5 Jun 1995 Continuation-in-part of Ser. No. WO 1995-US1790,
filed on 14 Feb 1995 Continuation-in-part of Ser. No. US 610651
Continuation-in-part of Ser. No. US 1996-696135, filed on 13 Aug 1996
Continuation-in-part of Ser. No. US 1995-461195, filed on 5 Jun 1995
Continuation-in-part of Ser. No. WO 1995-US1790, filed on 14 Feb 1995

PRAI US 2000-205417P 20000519 (60)
US 2000-198322P 20000419 (60)
US 1999-171677P 19991222 (60)
US 1999-163375P 19991103 (60)
US 1999-149935P 19990819 (60)
US 1999-148628P 19990812 (60)
US 1999-144024P 19990715 (60)
US 1999-143648P 19990714 (60)
US 1999-142343P 19990702 (60)
US 1997-39045P 19970228 (60)
US 1997-55561P 19970813 (60)
US 1996-23852P 19960813 (60)

DT Utility
FS GRANTED

LN.CNT 16222

INCL INCLM: 514/012.000
INCLS: 514/002.000; 530/399.000

NCL NCLM: 514/012.000
NCLS: 514/002.000; 530/399.000

IC [7]
ICM: A61K038-18
ICS: C07K014-50

EXF 514/2; 514/12; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 47 USPATFULL on STN
AN 2004:12971 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PI US 2004009491 A1 20040115
AI US 2002-264237 A1 20021004 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001,
PENDING

PRAI US 2000-205515P 20000519 (60)

DT Utility
FS APPLICATION

LN.CNT 18144

INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 530/388.100

NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 530/388.100

IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06; C07K016-30;
C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 47 USPATFULL on STN
AN 2004:7851 USPATFULL
TI Therapeutic agents useful for treating or preventing pain
IN Kyle, Donald J., Newtown, PA, UNITED STATES
Sun, Qun, Princeton, NJ, UNITED STATES
PI US 2004006091 A1 20040108
AI US 2003-374863 A1 20030227 (10)
PRAI US 2002-360172P 20020301 (60)

US 2002-411084P 20020917 (60)

DT Utility
FS APPLICATION
LN.CNT 3530

INCL INCLM: 514/254.030
INCLS: 544/367.000

NCL NCLM: 514/254.030
NCLS: 544/367.000

IC [7]
ICM: A61K031-496
ICS: C07D417-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 47 USPATFULL on STN
AN 2004:7345 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PI US 2004005579 A1 20040108
AI US 2002-264049 A1 20021004 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001,
PENDING
PRAI US 2000-209467P 20000607 (60)

DT Utility
FS APPLICATION
LN.CNT 18130

INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/320.100; 435/325.000; 435/069.300; 435/183.000;
530/350.000; 536/023.200; 514/012.000

NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/320.100; 435/325.000; 435/069.300; 435/183.000;
530/350.000; 536/023.200; 514/012.000

IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; A61K038-17; C12P021-02;
C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 47 USPATFULL on STN
AN 2003:282299 USPATFULL
TI Methods and compositions for treating inflammatory bowel diseases
relating to human tumor necrosis factor-gamma-beta
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Zhang, Jun, San Diego, CA, UNITED STATES
Wei, Ping, Brookeville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003198640 A1 20031023
AI US 2002-310793 A1 20021206 (10)
RLI Continuation-in-part of Ser. No. US 2002-226294, filed on 23 Aug 2002,
PENDING Continuation-in-part of Ser. No. US 2001-899059, filed on 6 Jul
2001, PENDING Continuation-in-part of Ser. No. US 2000-559290, filed on
27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-246129,
filed on 8 Feb 1999, PENDING Continuation-in-part of Ser. No. US
1998-131237, filed on 7 Aug 1998, PENDING Continuation-in-part of Ser.
No. US 1998-5020, filed on 9 Jan 1998, ABANDONED Continuation-in-part of
Ser. No. US 1995-461246, filed on 5 Jun 1995, ABANDONED
Continuation-in-part of Ser. No. WO 1994-US12880, filed on 7 Nov 1994,
PENDING
PRAI US 2001-336695P 20011207 (60)
US 2001-314381P 20010824 (60)
US 2001-278449P 20010326 (60)

US 2000-216879P 20000707 (60)
US 2000-180908P 20000208 (60)
US 1999-134067P 19990513 (60)
US 1999-132227P 19990503 (60)
US 1999-131963P 19990430 (60)
US 1998-74047P 19980209 (60)

DT Utility
FS APPLICATION

LN.CNT 14726

INCL INCLM: 424/145.100
NCL NCLM: 424/145.100
IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 47 USPATFULL on STN
AN 2003:265887 USPATFULL
TI Keratinocyte growth factor-2
IN Ruben, Steven M., Olney, MD, UNITED STATES
Jimenez, Pablo, Chatham, NJ, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Rampy, Mark A., Montgomery Village, MD, UNITED STATES
Mendrick, Donna, Mount Airy, MD, UNITED STATES
Zhang, Jun, Bethesda, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Coleman, Timothy A., Gaithersburg, MD, UNITED STATES
Gruber, Joachim R., Elizabethtown, KY, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
PA HUMAN GENOME SCIENCES, INC. (U.S. corporation)
PI US 2003186904 A1 20031002
AI US 2002-35212 A1 20020104 (10)
PRAI US 2001-259853P 20010108 (60)
US 2001-286368P 20010426 (60)
US 2001-331168P 20011109 (60)

DT Utility
FS APPLICATION

LN.CNT 17177

INCL INCLM: 514/044.000
INCLS: 514/012.000; 435/366.000
NCL NCLM: 514/044.000
NCLS: 514/012.000; 435/366.000

IC [7]

ICM: A61K048-00

ICS: A61K038-18; C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 47 USPATFULL on STN
AN 2003:258455 USPATFULL
TI (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions
thereof, and uses as a dopamine-reuptake inhibitor
IN Lippa, Arnold Stan, Ridgewood, NJ, UNITED STATES
Epstein, Joseph William, Monroe, NY, UNITED STATES
PA Dov Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003181508 A1 20030925
US 6716868 B2 20040406
AI US 2003-425545 A1 20030429 (10)
RLI Division of Ser. No. US 2001-939071, filed on 24 Aug 2001, GRANTED, Pat.
No. US 6569887
DT Utility
FS APPLICATION

LN.CNT 1256

INCL INCLM: 514/412.000
INCLS: 548/453.000
NCL NCLM: 514/412.000
NCLS: 548/452.000
IC [7]
ICM: A61K031-407

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 47 USPATFULL on STN
AN 2003:244856 USPATFULL
TI Therapeutic compositions and methods relating to prolactin releasing peptide (PrRP)
IN Civelli, Olivier, Irvine, CA, UNITED STATES
Lin, Steven, Upland, CA, UNITED STATES
PA Regents of the University of California (U.S. corporation)
PI US 2003171270 A1 20030911
AI US 2002-96777 A1 20020312 (10)
RLI Division of Ser. No. US 2000-560915, filed on 28 Apr 2000, GRANTED, Pat.
No. US 6383764
DT Utility
FS APPLICATION
LN.CNT 1706
INCL INCLM: 514/012.000
INCLS: 530/399.000; 514/255.040; 514/557.000
NCL NCLM: 514/012.000
NCLS: 530/399.000; 514/255.040; 514/557.000
IC [7]
ICM: A61K038-22
ICS: A61K031-496; A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 47 USPATFULL on STN
AN 2003:219663 USPATFULL
TI Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003152953 A1 20030814
AI US 2002-199869 A1 20020719 (10)
PRAI US 2001-306577P 20010719 (60)
DT Utility
FS APPLICATION
LN.CNT 12606
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 47 USPATFULL on STN
AN 2003:160075 USPATFULL
TI Colon and colon cancer associated polynucleotides and polypeptides
IN Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.
corporation)
PI US 2003109690 A1 20030612

AI US 2002-106698 A1 20020327 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000,
PENDING
PRAI US 1999-157137P 19990929 (60)
US 1999-163280P 19991103 (60)
DT Utility
FS APPLICATION
LN.CNT 17981
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 47 USPATFULL on STN
AN 2003:153320 USPATFULL
TI Protection, restoration, and enhancement of erythropoietin-responsive
cells, tissues and organs
IN Brines, Michael, Woodbridge, CT, UNITED STATES
Cerami, Anthony, Croton-On-Hudson, NY, UNITED STATES
Cerami, Carla, Sleepy Hollow, NY, UNITED STATES
PI US 2003104988 A1 20030605
AI US 2002-185841 A1 20020626 (10)
RLI Continuation of Ser. No. WO 2001-US49479, filed on 28 Dec 2001, PENDING
PRAI US 2000-259245P 20001229 (60)
DT Utility
FS APPLICATION
LN.CNT 2837
INCL INCLM: 514/008.000
INCLS: 514/012.000; 530/397.000
NCL NCLM: 514/008.000
NCLS: 514/012.000; 530/397.000
IC [7]
ICM: A61K038-24
ICS: C07K014-575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 47 USPATFULL on STN
AN 2003:145924 USPATFULL
TI Packaging of immunostimulatory substances into virus-like particles:
method of preparation and use
IN Bachmann, Martin, Winterthur, SWITZERLAND
Storni, Tazio, Viganello, SWITZERLAND
Maurer, Patrik, Winterthur, SWITZERLAND
Tissot, Alain, Zurich, SWITZERLAND
Schwarz, Katrin, Schlieren, SWITZERLAND
Meijerink, Edwin, Zurich, SWITZERLAND
Lipowsky, Gerd, Zurich, SWITZERLAND
Pumpens, Paul, Riga, LATVIA
Cielens, Indulis, Riga, LATVIA
Renhofa, Regina, Riga, LATVIA
PA Cytos Biotechnology AG (non-U.S. corporation)
PI US 2003099668 A1 20030529
AI US 2002-244065 A1 20020916 (10)
PRAI US 2001-318994P 20010914 (60)
US 2002-374145P 20020422 (60)
DT Utility
FS APPLICATION
LN.CNT 7907
INCL INCLM: 424/204.100
INCLS: 514/042.000; 514/012.000; 514/054.000; 514/008.000; 514/044.000;
514/292.000

NCL NCLM: 424/204.100
NCLS: 514/042.000; 514/012.000; 514/054.000; 514/008.000; 514/044.000;
514/292.000

IC [7]
ICM: A61K039-12

ICS: A61K038-17; A61K038-14; A61K048-00; A61K031-739; A61K031-4745

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 47 USPATFULL on STN

AN 2003:133508 USPATFULL

TI In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles

IN Bachmann, Martin F., Winterthur, SWITZERLAND
Lechner, Franziska, Zurich, SWITZERLAND
Storni, Tazio, Viganello, SWITZERLAND

PA Cytos Biotechnology AG (non-U.S. corporation)

PI US 2003091593 A1 20030515

AI US 2002-243739 A1 20020916 (10)

PRAI US 2001-318967P 20010914 (60)

DT Utility

FS APPLICATION

LN.CNT 6522

INCL INCLM: 424/204.100

INCLS: 424/186.100; 424/093.200

NCL NCLM: 424/204.100

NCLS: 424/186.100; 424/093.200

IC [7]

ICM: A61K048-00

ICS: A61K039-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 47 USPATFULL on STN

AN 2003:113075 USPATFULL

TI Nucleic acids, proteins, and antibodies

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PI US 2003077808 A1 20030424

AI US 2001-764891 A1 20010117 (9)

PRAI US 2000-179065P 20000131 (60)

US 2000-180628P 20000204 (60)

US 2000-214886P 20000628 (60)

US 2000-217487P 20000711 (60)

US 2000-225758P 20000814 (60)

US 2000-220963P 20000726 (60)

US 2000-217496P 20000711 (60)

US 2000-225447P 20000814 (60)

US 2000-218290P 20000714 (60)

US 2000-225757P 20000814 (60)

US 2000-226868P 20000822 (60)

US 2000-216647P 20000707 (60)

US 2000-225267P 20000814 (60)

US 2000-216880P 20000707 (60)

US 2000-225270P 20000814 (60)

US 2000-251869P 20001208 (60)

US 2000-235834P 20000927 (60)

US 2000-234274P 20000921 (60)

US 2000-234223P 20000921 (60)

US 2000-228924P 20000830 (60)

US 2000-224518P 20000814 (60)

US 2000-236369P 20000929 (60)

US 2000-224519P 20000814 (60)

US 2000-220964P 20000726 (60)

US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)

US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DT Utility
FS APPLICATION
LN.CNT 59131
INCL INCLM: 435/226.000
INCLS: 435/325.000; 435/320.100; 435/069.100; 435/069.400; 530/399.000;
536/023.100
NCL NCLM: 435/226.000
NCLS: 435/325.000; 435/320.100; 435/069.100; 435/069.400; 530/399.000;
536/023.100
IC [7]
ICM: C12N009-64
ICS: C07K014-575; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 47 USPATFULL on STN
AN 2003:105826 USPATFULL
TI Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IN Brines, Michael, Woodbridge, CT, UNITED STATES
Cerami, Antony, Croton On Hudson, NY, UNITED STATES
Cerami, Carla, Sleepy Hollow, NY, UNITED STATES
PI US 2003072737 A1 20030417
AI US 2002-188905 A1 20020703 (10)
RLI Continuation-in-part of Ser. No. US 2000-753132, filed on 29 Dec 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US49479, filed on 28 Dec 2001, PENDING
PRAI US 2000-259245P 20001229 (60)
DT Utility
FS APPLICATION
LN.CNT 3417
INCL INCLM: 424/085.100
INCLS: 530/351.000
NCL NCLM: 424/085.100
NCLS: 530/351.000
IC [7]
ICM: A61K038-19
ICS: C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 47 USPATFULL on STN
AN 2003:93613 . USPATFULL
TI Methods for inhibiting cognitive deterioration in adults with down's syndrome
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES
PA Corcept Therapeutics, Inc. (U.S. corporation)
PI US 2003064974 A1 20030403
AI US 2002-230575 A1 20020828 (10)
PRAI US 2001-316653P 20010831 (60)
DT Utility
FS APPLICATION
LN.CNT 1295
INCL INCLM: 514/179.000
NCL NCLM: 514/179.000
IC [7]
ICM: A61K031-573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 47 USPATFULL on STN
AN 2003:65443 USPATFULL
TI (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
IN Lippa, Arnold Stan, Ridgewood, NJ, UNITED STATES
Epstein, Joseph William, Monroe, NY, UNITED STATES
PI US 2003045567 A1 20030306
US 6569887 B2 20030527
AI US 2001-939071 A1 20010824 (9)
DT Utility
FS APPLICATION
LN.CNT 1255
INCL INCLM: 514/413.000
INCLS: 548/453.000
NCL NCLM: 514/412.000
NCLS: 548/452.000
IC [7]
ICM: C07D487-02
ICS: A61K031-407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 44 OF 47 USPATFULL on STN
AN 2002:102277 USPATFULL
TI Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
IN Civelli, Olivier, Irvine, CA, United States
Lin, Steven, Upland, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6383764 B1 20020507
AI US 2000-560915 20000428 (9)
DT Utility
FS GRANTED
LN.CNT 1555
INCL INCLM: 435/007.800
INCLS: 435/007.200; 514/002.000; 436/501.000
NCL NCLM: 435/007.800
NCLS: 435/007.200; 436/501.000; 514/002.000
IC [7]
ICM: G01N033-53
ICS: G01N033-566; A61K038-00
EXF 436/503; 436/517; 436/501; 514/2; 435/7.2; 435/7.21; 435/7.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 47 USPATFULL on STN
AN 2002:66880 USPATFULL
TI Screening and therapeutic methods for promoting wakefulness and sleep
IN Civelli, Olivier, Irvine, CA, UNITED STATES
Lin, Steven, Upland, CA, UNITED STATES
PI US 2002037533 A1 20020328
AI US 2001-932161 A1 20010817 (9)
RLI Continuation-in-part of Ser. No. US 2000-560915, filed on 28 Apr 2000,
PENDING
DT Utility
FS APPLICATION
LN.CNT 2464
INCL INCLM: 435/007.100
INCLS: 514/001.000
NCL NCLM: 435/007.100
NCLS: 514/001.000
IC [7]
ICM: G01N033-53
ICS: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 47 USPATFULL on STN
AN 2002:63894 USPATFULL
TI Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists
IN Schatzberg, Alan F., Los Altos, CA, United States
Belanoff, Joseph K., Cupertino, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PI US 6362173 B1 20020326
AI US 2000-639377 20000815 (9)
RLI Continuation of Ser. No. US 1999-244457, filed on 4 Feb 1999, now patented, Pat. No. US 6150349 Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998
PRAI US 1997-60973P 19971006 (60)
DT Utility
FS GRANTED
LN.CNT 1515
INCL INCLM: 514/179.000

NCL NCLM: 514/179.000

IC [7]

ICM: A61K031-56

EXF 514/179

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 47 USPATFULL on STN

AN 2000:157400 USPATFULL

TI Methods for treating psychosis associated with glucocorticoid related dysfunction

IN Schatzberg, Alan F., Los Altos, CA, United States
Belanoff, Joseph K., Cupertino, CA, United States

PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)

PI US 6150349 20001121

AI US 1999-244457 19990204 (9)

RLI Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998

PRAI US 1997-60973P 19971006 (60)

DT Utility

FS Granted

LN.CNT 1515

INCL INCLM: 514/179.000

NCL NCLM: 514/179.000

IC [7]

ICM: A61K031-56

EXF 514/179

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:57:11 ON 20 APR 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE,
SCISEARCH' ENTERED AT 18:57:57 ON 20 APR 2005

L1 113468 S NICOTINE OR (NICOTINE DERIVATIVE)

L2 2052 S L1 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

L3 47 S L2 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS

L4 10 S L3 AND (BINDING AGENT#)

L5 3873 S L1 AND (METABOLITE OR (DEGRADATION PRODUCT))

L6 295 S L5 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

L7 14 S L6 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS

=> s 15 and ((COPD) or (chronic obstructive pulmonary disease))

L8 90 L5 AND ((COPD) OR (CHRONIC OBSTRUCTIVE PULMONARY DISEASE))

=> s 18 and (pharmaceutically acceptable carrier)

L9 54 L8 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)

=> s 19 and (intravenous? and transdermal? and oral? and intranasal? and
intravaginal?)

L10 3 L9 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANASAL?
AND INTRAVAGINAL?)

=> d 110 1-3 ibib abs

L10 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:12971 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004009491 A1 20040115
 APPLICATION INFO.: US 2002-264237 A1 20021004 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed
 on 18 May 2001, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2000-205515P	20000519 (60)
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS: 24	
EXEMPLARY CLAIM: 1	
LINE COUNT: 18144	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 3 USPATFULL on STN
 ACCESSION NUMBER: 2004:7345 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

NUMBER	KIND	DATE
PATENT INFORMATION: US 2004005579	A1	20040108
APPLICATION INFO.: US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

NUMBER	DATE
PRIORITY INFORMATION: US 2000-209467P	20000607 (60)
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS: 24	
EXEMPLARY CLAIM: 1	
LINE COUNT: 18130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:160075 USPATFULL
TITLE: Colon and colon cancer associated polynucleotides and polypeptides
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steve C., Rockville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17981	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer

associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:57:11 ON 20 APR 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE,
SCISEARCH' ENTERED AT 18:57:57 ON 20 APR 2005

L1 113468 S NICOTINE OR (NICOTINE DERIVATIVE)
L2 2052 S L1 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)
L3 47 S L2 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS
L4 10 S L3 AND (BINDING AGENT#)
L5 3873 S L1 AND (METABOLITE OR (DEGRADATION PRODUCT))
L6 295 S L5 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)
L7 14 S L6 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS
L8 90 S L5 AND ((COPD) OR (CHRONIC OBSTRUCTIVE PULMONARY DISEASE))
L9 54 S L8 AND (PHARMACEUTICALLY ACCEPTABLE CARRIER)
L10 3 S L9 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANAS

=> s l8 and (intravenous? and transdermal? and oral? and intranasal? and
intravaginal?)

L11 3 L8 AND (INTRAVENOUS? AND TRANSDERMAL? AND ORAL? AND INTRANASAL?
AND INTRAVAGINAL?)